• GolfLync has tapped and fulfills a confirmed need in a strong market, like the most successful fast-growing companies that have come before it
• GolfLync does a superior job of engaging and bringing together the expanding golf community, using intelligent technology with a user-friendly interface
• Remarkable membership growth, a far above average conversion rate, and high social media ratings, point to a unique opportunity for investors as well as golf lovers

Usually defined as a startup that is privately owned with a valuation that exceeds $1 billion, a unicorn is the epitome of spectacular growth. Although being a unicorn doesn’t guarantee permanent success, the most famous former unicorns, such as Google (NASDAQ: GOOGL), Facebook (NASDAQ: META), and Airbnb (NASDAQ: ABNB), now have astronomical market caps, with Google’s topping out at over $1.5 trillion. Every one of them started out small, but with an idea that filled a real need, fueling rapid growth and investment. In particular, social media apps that empower the building of specialized online communities can soar on word-of-mouth alone.

GolfLync is soaring due to its unique and feature-strong ability to bring together people who love golf, a sport that is experiencing a post-pandemic revival, and a market that was already listed at $26.1 billion in 2022 (26 Glorious Golf Industry Statistics [2023]: How Big Is The Golf Industry – Zippia). The app (available as a free download on the Apple App Store and the Google Play Store) is powered by an intelligent algorithm that brings golfers together based upon a balanced range of factors, including handicap, preferred playing style, and location, along with various related interests and specifications. The app readily supports everything from matching individual partners to building large and diverse groups called “Virtual Golf Clubs”(TM). These GolfLync VGCs are becoming especially popular, and now spread around the country.

GolfLync CEO Noah DiPasquale says “It basically operates like Tinder for golfers”, while Michael Quiel, Co-Founder, summed it up: “Our commitment to providing a user-friendly and feature-rich platform has driven the exceptional growth and engagement we are witnessing.” According to the company, GolfLync has seen a 15x growth in membership in just the past 4 months. In addition, GolfLync has a social media conversion rate greater than 52%, compared to the average conversion rate of less than 33%, and has now reached the 75th percentile for user conversions as shown in the Apple Store. The GolfLync platform currently exceeds 200 ratings on the Apple App store with 5-star average.

You can download the GolfLync app using the following links:

• Android: GolfLync – Apps on Google Play 
• iPhone: ‎GolfLync

For more information about GolfLync, visit the company’s website at www.GolfLync.com.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”)
• The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”)
• The orphan drug designation (“ODD”) in combination with the FTD is an indication of the great need for better treatment options for patients with ES-SCLC, and non-small cell lung cancer (“NSCLC”), according to Genprex President, Chairman, and CEO Rodney Varner
• With the receipt of the latest FTD and the orphan drug status, Genprex is looking forward to initiating the Acclaim-3 clinical trial, planned for the fourth quarter of 2023

Genprex (NASDAQ: GNPX), a clinical-stage company developing life-changing gene therapies for patients with cancer and diabetes, recently celebrated an important milestone: the award of an orphan drug designation. The company announced August 10 that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”) (https://ibn.fm/J4gpJ).

The FDA grants orphan drug status to a drug or biological product that prevents, diagnoses, or treats a rare disease or condition as part of the agency’s efforts to prioritize the development and evaluation of new treatments for rare diseases (https://ibn.fm/0PN7j). The ODD grants a sponsor – in this case, Genprex – incentives such as tax credits for qualified clinical trials and an exemption from user fees. Perhaps most importantly, the orphan drug designation grants potential seven-year exclusivity post-approval. The global SCLC therapeutics market is projected to grow at a CAGR of 12.3% from $5.12 billion in 2022 to $16.33 billion by 2032 (https://ibn.fm/y50nf).

The Orphan Drug Act (“ODA”) of 1983 defines rare diseases as those affecting “less than 200,000 persons in the United States.”  The FDA interprets this to mean that the prevalence of the disease, that is the number of people affected by the disease at a particular point in time, must be less than 200,000.  This is different than the incidence of the disease, which is the number of people newly diagnosed with SCLC during the course of a year (https://ibn.fm/cpEOA).

Based on the orphan drug definition SCLC is classified as a rare disease because the prevalence of SCLC is less than 200,000 cases in the US. The condition accounts for 13-15% of all lung cancer cases, and in the United States, about 238,440 adults will be diagnosed with lung cancer in 2023. The condition also presents a poor prognosis, partly because a majority of people – more than 60% – with SCLC are diagnosed after the cancer has spread outside the lung (https://ibn.fm/F7jpN). In such cases, the condition is known as extensive-stage SCLC (“ES-SCLC”).

Patients with ES-SCLC are given combination chemotherapy as the first-line treatment, with varying overall response rates of 44-78% and median progression-free survival (“mPFS”) that ranges between 4.3 and 5.7 months, depending on the selected combination (https://ibn.fm/gyNaW). Patients also undergo maintenance therapy, an ongoing cancer treatment, after the initial response to the first recommended treatment. The mPFS for patients receiving Genentech, Inc.’s Tecentriq(R) as maintenance treatment is only 2.6 months from the start of maintenance treatment, suggesting a substantial need for improvement in maintenance therapy, according to Genprex.

Genprex’s efforts to meet this need received a boost in June 2023 when the FDA granted Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment (https://ibn.fm/wsBrh).

“We are excited to receive Orphan Drug Designation from the FDA for REQORSA for patients with SCLC,” commented Rodney Varner, President, Chairman, and CEO of Genprex. “This FDA Orphan Drug Designation in combination with our recently received FDA Fast Track Designation underscores the great need for better treatment options for patients with SCLC, ES-SCLC, and non-small cell lung cancer.”

Genprex’s lung cancer programs now have three FDA Fast Track Designations. In January 2020, the company announced that the FDA had granted an FTD for REQORSA in combination with AstraZeneca’s Tagrisso(R) for patients with NSCLC whose condition progressed after treatment with Tagrisso (https://ibn.fm/aSxQG). Later, in January 2022, the company announced it had received an FTD for REQORSA Immunogene Therapy in combination with Merck & Company’s Keytruda(R) in patients with NSCLC whose disease progressed after treatment with Keytruda (https://ibn.fm/L7Z1S).

With the receipt of the latest FTD and the orphan drug status, Genprex is looking forward to initiating the Acclaim-3 clinical trial, expected in the fourth quarter of 2023. Acclaim-3 is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• GEMXX recently announced that new investments had strengthened its financial position and would allow it to attract further investment over the next 12 months
• The announcement followed the acquisition of a 50% ownership stake in Crazy Horse Mining Inc., whose assets include a 100% interest in the Snow Creek and Rosella Creek gold projects in British Columbia
• Initial production results on the Snow Creek site prop GEMXX to scale up gold production, having announced plans to ramp up processing to approximately 1,000 cubic yards of gold-bearing ore per day

GEMXX (OTC: GEMZ), a publicly traded vertically integrated company specializing in producing and distributing gemstones and jewelry globally, using its own gold and Ammolite mining resources, is already seeing a return on key investments. Stemming from its ambitious growth plan, the company has ventured into untapped markets, exploring acquisitions and further integrating critical services, distribution networks, and retail outlets into its fold, all of which have shown great promise from a return on investment (“ROI”) standpoint.

As the only public company doing what it does, specifically engaging in Ammolite mining worldwide, GEMXX represents several firsts, including charting the path for other players in its industry. As it owns its reserves, the company currently enjoys a significant cost-saving edge over other producers in the gemstone and jewelry market, a leverage that allows it to explore other ambitious investment opportunities.

Just recently, GEMXX announced that new investments had strengthened its financial position, providing new energy to fulfill its growth strategy for the year. It also noted that the strengthened financial position would aid in situating the company’s market positioning, allowing it to attract further investment over the next 12 months. This followed the acquisition of a 50% ownership stake in Canadian gold mining company Crazy Horse Mining Inc., with an estimated recovery rate of 100,000 ounces of gold from its sites.

“We are tremendously pleased with the development of the Company over the past several months, and we are extremely excited for the anticipated growth,” noted Jay Mauli, GEMXX’s Founder, Chairman and CEO (https://ibn.fm/DoPh9).

Crazy Horse’s assets include a 100% interest in the Snow Creek and Rosella Creek gold projects, both spread across more than 700 acres in British Columbia. On August 15, GEMXX announced the completion of its first clean-out and recording of gold production on the site for the 2023 mining season. A 4,500-cubic-yard sample of gold-bearing surface ore was processed, ultimately providing a “positive indication of the resource potential on the property” (https://ibn.fm/DSrjg).

Most notably, the initial production results yielded 38.73 ounces of gold from 4,500 cubic yards of surface material, amounting to 0.86 ounces per 100 cubic yards. These results prop GEMXX to scale up gold production, having announced plans to ramp up processing to approximately 1,000 cubic yards of gold-bearing ore daily.

Through investments such as these, coupled with executing its overall business plan, GEMXX is positioning itself as a market leader. Additionally, it is inching closer to being fully integrated from mine to market while readying itself for any economic condition. Most importantly, these moves indicate the company’s commitment to creating shareholder value.

“We intend to do everything necessary to drive shareholder value,” noted Mr. Mauli.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/scLU3) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

The largest B2B cannabis industry event in New Jersey – NECANN’s New Jersey Cannabis Convention – returns to Atlantic City on September 8-9, 2023. Now in its 4th year, the event, which is part of the largest cannabis and hemp convention series in the world, continues to grow as the New Jersey cannabis market develops. It comes more than a year after the state legalized the sale of recreational marijuana, which led to the April 2023 opening of the first licensed recreational marijuana dispensary in Atlantic City (https://ibn.fm/t15j2).

With such stores finally opening and the number of licenses rapidly increasing, the number of ancillary businesses, entrepreneurs, investors, cultivators, medical dispensaries, license holders, and suppliers, is increasing by the day. Conveniently, NECANN’s New Jersey Cannabis Convention is designed for this category of budding industry players and entrants, among others. The event represents everything that touches cannabis and promises to be the perfect setting for attendees to learn about the industry.

“There’s everything here that you could possibly learn about the cannabis industry. Everything from grow lights, payment processors, banking, [and] accounting. If you are looking to start any type of cannabis business, you can come to NECANN and learn whatever you are trying to learn,” said Brian O’Connor of Paybotic, a payment processor that enables cannabis businesses to transact, in a video recapping the 2021 event (https://ibn.fm/5npQw).

What makes the New Jersey Cannabis Convention particularly appealing to startups is the fact that it is an opportunity to meet similar sprouting businesses. Even so, the event is equally suited for exhibitors drawn from every niche within the cannabis industry. Attracting thousands of cultivators, industry professionals, educators, and advocates, from hundreds of local and national companies, the New Jersey Cannabis Convention promises a lot of foot traffic, much to the advantage of vendors and businesses showcasing their products. In fact, exhibitors who were part of previous editions of the event have lauded its role in bringing them closer to investors and potential business partners. The 2023 event will be no different, so reserve your exhibit space today.

For attendees in pursuit of knowledge, there’s more! The activity-packed two-day event features learnings from expert speakers delivered through dozens of planned sessions. Moreover, there are plenty of networking opportunities. The New Jersey Cannabis Convention is the perfect setting to learn, meet, and network. So do not miss it – register today.

For more information, please visit https://ibn.fm/IWEr5

• SuperCom, through its fully-owned subsidiary, Leaders in Community Alternatives (“LCA”), just closed a multi-million dollar contract in California that will run until 2026
• The contract marks another substantial achievement for SuperCom, building on a track record of securing numerous electronic monitoring contracts in the U.S. and Europe
• The company’s management notes how well it is positioned to help the electronic monitoring industry move into the future

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity security solutions offering advanced safety, identification, and security products and solutions to governments, just closed a multi-million dollar contract in California. The contract, secured through SuperCom’s fully-owned subsidiary, Leaders in Community Alternatives (“LCA”), will see the company provide alcohol monitoring technologies and services in the state and will run until 2026, including an initial 3-year period with the potential for future extensions (https://ibn.fm/g8Kuh).

“Our reputation for providing reliable and high-quality electronic monitoring services was pivotal in securing the contract,” noted Ordan Trabelsi, SuperCom’s President and CEO. “We are proud to have been chosen once again to support California’s criminal justice system,” he added.

The contract marks another substantial achievement for SuperCom, building on a track record of securing numerous electronic monitoring (“EM”) contracts in the U.S. and Europe. Thus far, through its EM platforms, the company has helped governments and national agencies design, launch, and operate numerous EM programs worldwide (https://ibn.fm/fauLo).

SuperCom has also made a name for itself in the cybersecurity space. Through two key acquisitions – Prevision Ltd. and Safend Ltd., the company has positioned itself as an international provider of cutting-edge endpoint data protection, encryption, and comprehensive device and port control.

The electronics monitoring solutions market is expected to hit $2.1 billion in 2026, while the global cybersecurity market is expected to be valued at $266.2 billion by 2027.

“As we move forward, we remain committed to fostering strong partnerships, driving technological advancements, and delivering top-tier solutions that address the unique challenges faced by the criminal justice system,” noted Ordan.

The company’s management believes these moves position it to help lead the electronic monitoring industry into the future. The California contract validates SuperCom’s current market position while affirming its commitment to delivering high-quality services and cutting-edge monitoring solutions to government agencies.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Eloro Resources recently published a new corporate update detailing ongoing developments within the company
• Eloro is continuing to work on the upcoming publication of its inaugural NI 43-101 compliant mineral resource estimate report, which will provide the market with more granular information related to the commercial viability of the Iska Iska project
• The company has recently carried out a variety of further studies within the site, including looking into the viability of ‘ore sorting’, a determinant of overall resource extraction efficiency

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mining company focused on developing its potential world-class Iska Iska silver-tin polymetallic property located in the Potosi Department in southern Bolivia, recently provided investors and corporate stakeholders with an overview of the company’s ongoing developments. With the company having engaged in exhaustive exploratory drilling and analysis activities dating back to the inception of the Iska Iska project, Eloro Resources are now embarked on the process of finalizing the release of their initial mineral resource estimate (“MRE”) report, which will seek to provide the market with further granularity as to the Iska Iska property’s viability as a commercial mining operation going forward (https://ibn.fm/qUmUv).

Previously exploited by artisanal miners in the early 1960s, repeated surveys of Eloro’s Iska Iska and Mina Casiterita properties – the latter situated to Iska Iska’s immediate southwest, have outlined the appearance of an extensive, near surface, magnetic intrusive body spread across the two sites. These findings have been further complemented by an extensive program of exploratory drill work across the sites- dating back to early 2021 and amounting to a cumulative 85,000 meters of diamond drilling across 122 individual holes. Recent conclusions drawn from this drill work have driven the mining company to vastly increase their initial projections related to the potential scale of the deposit at hand; Eloro’s most recent model now suggests that the company could potentially have access to a high-grade deposit (defined as having potential deposits of > 90g AG eq/t) measuring 800 meters wide and over 1,100 meters in depth.

In addition to its drill work, Eloro Resources have sought to measure the potential refining efficiency of the site, factors which will ultimately influence the commercial viability of a site should mining activity formally commence.  Preliminary tests carried out at TOMRA in Germany have found the mineralization at Iska Iska to be amenable to ‘ore sorting’; in effect, the tests have found that at least 40 percent of the waste within the Iska Iska site’s Polymetallic domain and up to 80 percent of the waste in the Tin domain may be removed prior to submitting the ore for further refining. In effect, this will increase the concentrator feed grades, thus reducing future operating costs and significantly decreasing the cut-off grades (“COG”) for the upcoming mineral resource estimate report.

In the coming weeks, Eloro Resources expect to publish their inaugural NI 43-101 compliant mineral resource estimate relating to the Santa Barbara High-Grade Zone, situated within the Iska Iska property site. Meanwhile, however, the company has continued its exploratory mining work spread across a wide array of areas within the Iska Iska and Mina Casiterita properties. Initial diamond drilling and geophysical surveys verifying the potential of a major tin porphyry located to the south of Iska Iska and southwest of Casiterita have been carried out, with results currently pending. Simultaneously, recent drill intersections, inverse magnetic models and deep drill intersections have opened up the possibility of a major tin porphyry beneath the Porco area to the south and extending into Mina Casiterita.

With Eloro Resources’ initial MRE report soon to be published – followed shortly thereafter by a preliminary economic assessment (“PEA”) report – Eloro Resources continues to march resolutely on towards an eventual future entailing commercial mining operations within its flagship Iska Iska site.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• GEMXX Corporation is a unique vertically integrated jewelry producer, focused on managing costs in-house by mining its own gold and gemstones via its Canadian mine resources for its many jewelry products
• GEMXX has been engaged this year in bringing one of its British Columbia gold ore sites up to full production
• The company recently announced the encouraging results of gold ore processed from surface materials stockpiled during site construction, amounting to 0.86 ounces per 100 cubic yards
• GEMXX will add the gold processed from the site to fossilized, iridescent Ammolite gemstones from its Alberta resources, as the materials for its jewelry

Mine-to-market global jewelry producer GEMXX (OTC: GEMZ) is increasing its capacity for gold ore processing at one of the company’s Canadian assets, enthusiastic over the better-than-expected amount of ore produced from stockpiled surface material.

GEMXX’s Snow Creek Mine property in British Columbia completed site preparation for gold processing last year and mobilized equipment in May to begin bringing the property into full production (https://ibn.fm/ah7a9). GEMXX reported the first production of gold from the site on Aug. 15 as ore collected from a 4,500-cubic-yard sample during construction of the facility was “cleaned out.”

The operation yielded 38.73 ounces of gold, amounting to 0.86 ounces per 100 cubic yards, according to the company’s statement (https://ibn.fm/JNtFk).

“These results are a promising start to what is anticipated to be a highly lucrative first year of gold mining,” Ian McClintock, the president of GEMXX’s exploration partner Crazy Horse Mining Inc., stated in the news release.

GEMXX is anticipating that gold ore from the 498-acre site, together with ammolite from its Alberta resources, will bolster the company’s long-term plans to expand its jewelry production and “de-risk revenues,” CEO Jay Maull added.

GEMXX has also acquired a second gold resource in British Columbia — the 240-acre Rosella Creek project. Initial testing at the two sites has led the company to estimate the properties could yield over 100,000 ounces of easily recoverable gold.

GEMXX has scheduled an S-K 1300-compliant Resource Report to be completed this summer to provide verification of its estimate.

“The acquisition of the Snow Creek and Rosella Creek gold asset … complements our ammolite production with the world’s most sought-after commodity. This will provide GEMXX with a significant reduction in the cost of goods for our entire gold jewelry product line and will bring the Company one step closer to our goal of becoming vertically integrated,” Maull stated. 

The company has contracted with publicity agencies this year to increase brand awareness of its operations, and has begun fund-raising efforts for its Reg A offering, which is fully qualified for $6 million at 40 cents per share (https://ibn.fm/2fBx0).

Ammolite, the gemstone that has been the centerpiece of GEMXX’s jewelry production, is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses. Alberta is the only place in the world where the gem is mined commercially, thanks apparently to historical conditions unusual to the region, since only select ammonite fossils result in ammolites, according to research published by the University of Alberta (https://ibn.fm/hQmfh).

Ammolites were only formally recognized as a gemstone in 1981, but are now valued for their iridescent colors, which are a result of alternating layers of the mineral aragonite and the protein in the ammonites’ shells, the article states.

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV
• Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat
• The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results

As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

Renovaro’s oncology platform is now at the forefront of the company’s development activities – primarily focused on pancreatic cancer. The company also plans to include other solid tumors with short life expectancy in the first human Phase I/IIa studies that are on track for mid-2024. Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat.

The company’s novel technology uses cell and gene therapies to promote a renewed immune response against solid tumors. Dr. Anahid Jewett, a renowned cancer researcher at UCLA, independently conducted Renovaro’s two humanized mouse model tests using the company’s novel dendritic cell-based therapy. These important findings were presented at two scientific conferences and were the foundation supporting a pre-IND submission to the US Food and Drug Administration (“FDA”). Notably, the findings from Dr. Jewett’s study consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro’s current product development pipeline includes the following:

• RENB-DC11 – an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors
• RENB-HV12 – an engineered allogeneic T-Cell vaccine and HIV vaccine candidate with IND submission is expected in the second half of 2024
• RENB-HV21 – another potential therapy for HIV that shows promising preliminary results, Renovaro holds an exclusive license and has completed the Pre-IND submission with potential IND submission and human trials expected in 2024
• RENB-HV01 – Caring Cross, a non-profit corporation, has entered into a sublicense to share profits if the product is commercialized, which has shown that proprietary CAR-T cells cure HIV in mouse models
• RENB-HB01 – a therapeutic approach that aims to eliminate HBV rapidly, with a two to three-dose treatment regimen

Renovaro recently announced the execution of a binding, exclusive letter of intent (“LOI”) with GEDi Cube, a cutting-edge health AI company. Renovaro’s officials are confident that joining forces with GEDi Cube will help enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.

“Our advanced cell, gene, and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms,” said Dr. Mark Dybul, CEO of Renovaro (https://ibn.fm/L54YI). “I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• SuperCom recently released its second quarter and first half 2023 results for the period ended June 30, 2023
• Financial highlights included a 141% YoY increase in quarterly revenue and a 126% YoY increase in half-year revenue to $7.7 million and $14.1 million, respectively
• The company reported a 106% increase in trailing-twelve-month revenue to $25.5 million from $12.4 million
• SuperCom provided business highlights, documenting its recently awarded contracts and projects in Europe (Romania, Finland, and Iceland) as well as in the US
• President and CEO Ordan Trabelsi credits the company’s investments in research and development as well as sales and marketing for its ability to land global opportunities and displace incumbents

SuperCom (NASDAQ: SPCB), a global provider of traditional and digital identity solutions, providing advanced safety, identification, Internet of Things (“IoT”), connectivity, and security solutions to governments and private and public organizations globally, recently released its financial and operating results for the three and six months ended June 30, 2023, as well as financial highlights for the trailing-twelve-month period (https://ibn.fm/7seN6).

“We are excited to announce breakthrough performance for Q2 2023, where we outperformed expectations on multiple fronts. Our efforts have catapulted us to new heights, realizing a substantial 141% year-over-year (“YoY”) revenue growth, as well as record-breaking quarterly revenue of $7.7 million and non-GAAP earnings per share (“EPS”) of $0.07. Furthermore, this quarter closes an exceptional trailing twelve-month period boasting $25.5 million in revenue and $2.5 million in EBITDA, underscoring our focus on sustained growth and profitability,” said SuperCom President and CEO Ordan Trabelsi.

SuperCom celebrated a fourth consecutive quarter of high YoY revenue growth, reporting a 141% increase in revenue to a five-year record of $7.7 million, up from $3.2 million recorded in Q2 2022. Its gross profit for this reporting period grew 77% to $2.3 million from $1.3 million. The company also ended the quarter with working capital of $21.2 million. Furthermore, results from the just-ended quarter contributed to half-year revenue of $14.1 million for the first half of fiscal 2023, a 126% YoY increase from $6.3 million, as well as a gross profit of $3.9 million, representing an increase YoY of 47% from $2.6 million.

Other notable highlights included a 106% YoY increase in trailing twelve-month revenue to $25.5 million from $12.4 million. In his address to shareholders during a conference call held July 31, 2023, Trabelsi attributed this growth to the IoT division, the company’s “primary growth engine” (https://ibn.fm/3QY0O). Putting things into perspective, Trabelsi said, “While the global electronic monitoring market grows at approximately 11% per year, SuperCom’s IoT revenue achieved over 100% growth in the past twelve months, outpacing the global market growth by over a multiple of 10x. This growth is a testament to the fact that the market prefers our solution over alternatives.”

SuperCom also provided business updates, discussing the recently awarded contracts and projects worldwide. The company, the press release stated, is well on track with the implementation of a $33 million national electronic monitoring (“EM”) project in Romania, which covers domestic violence protection, GPS tracking of offenders, and home detection monitoring and uses the company’s PureSecurity EM Suite. 

In Europe, the company has deployed the PureSecurity EM Suite in Finland as part of a national project with the national government, covering programs such as GPS tracking, house arrest, and inmate monitoring. The project, launched in Q1 2023, is valued at $3.6 million. SuperCom has also launched a new project in Iceland.

Moreover, the company’s wholly-owned subsidiary, LCA, won a $4.25 million contract to provide adult reentry services in a county in Northern California, US. The project, which began in Q1 2023 and expanded LCA’s existing EM and day reporting services to include community-based and jail-based sites, is actively servicing clients and generating recurring revenue, according to the company.

SuperCom also celebrated other milestones, including the completion of the development and multiple successful deployments of PureProtect, its life-saving domestic violence monitoring solution, and the launch in various regions of the US of PureOne, its best-in-class all-in-one GPS tracking ankle-bracelet monitoring solution. SuperCom is prioritizing the expansion of PureOne into new markets and geographies.

“SuperCom’s proprietary technology has been a game-changer in competitive tenders worldwide, enabling us to displace incumbent vendors and make a significant impact on public safety around the globe. Our steadfast commitment to technology superiority is evident in our recent incorporation of AI capabilities into our products, along with the continuous launch of innovations such as the recent PureProtect and PureOne solutions. These efforts propel our business growth and solidify our path toward industry leadership,” Trabelsi explained.

According to Trabelsi, the company’s investments in research and development as well as sales and marketing have paved the way for global opportunities, enabling it to deliver exceptional value to its growing list of clients while turbocharging its resolve to meet its long-term objectives.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

Counterculture retail professionals, business executives, researchers, and industry leaders, are invited to attend Alternative Products Expo to be held in Las Vegas from September 14-16, 2023.  Dedicated to promoting creativity, the much-awaited event will be focused on eco-friendly solutions and alternative products. The Expo is set to engage audiences with a wide range of unique and sustainable products that signify the latest trends and technological advancements.

The Expo aims to empower participants to make informed buying decisions while contributing to a progressive, more sustainable future. By showcasing a wide range of ethically sourced and environmentally friendly alternatives, the Expo is about creating a socially responsible community that aligns with technological innovations and sustainable best practices.

Alternative Products Expo will feature a diverse group of eco-conscious entrepreneurs, business leaders, and innovators, providing insights into the intricacies of sustainable products while enlightening attendees about market potential and current opportunities.

Innovation meets Sustainability

Alternative Products Expo promises to provide an immersive experience through engaging workshops, enlightening exhibits, and best-in-class networking opportunities. Attendees will get a unique opportunity to meet industry leaders and learn from their experience spanning a range of industries, including renewable energy, vaping, beverages, and more.

Experience the blend of creativity and sustainability as top industry leaders showcase their collections. From fair trade practices to upcycled materials, the Expo will reveal unique, game-changing ideas that drive innovation in style. Business owners will exhibit their newest products, challenging the boundaries and redefining innovation.

Thought-provoking seminars and workshops will enable attendees to learn about the latest innovations in the alternative products industry, from zero-waste packaging to renewable energy solutions.

To learn more, please visit https://ibn.fm/21jUz